Increased Offering Size Secures Funding for Late-Stage Clinical Trials

Braveheart Bio, Inc. (BRVE) successfully completed an IPO on August 6, 2026, issuing 21.25 million shares at $18 per share, raising a total of $382.5 million. This exceeded the initially planned 18.75 million shares and the target price range of $15-$17, indicating strong institutional demand for its late-stage cardiovascular asset. The proceeds will be used to fund the global Phase 3 clinical trial of BHB-1893, expand manufacturing capacity, and cover operating expenses. However, the company's reliance on a single candidate means its valuation is directly tied to the success of the Phase 3 trial and regulatory progress.

BHB-1893 Directly Addresses the Cause of Heart Contraction

BHB-1893 is a clinical-stage, oral, selective small molecule cardiac myosin inhibitor (CMI) without a separate brand name, known as HRS-1893 in Hengrui Pharma's development program. It works by inhibiting cardiac myosin ATPase, reducing excessive actin-myosin cross-bridging and myocardial contraction. In a Phase 2 clinical trial for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the complete response rate, defined as a reduction in left ventricular outflow tract (LVOT) pressure gradient to less than 30 mmHg, reached 86% in the highest dose group, with a reduction in left ventricular ejection fraction (LVEF) ranging from 1.8% to 2.7%. The key to differentiation lies in whether the rapid efficacy and limited LVEF reduction observed in the Phase 2 trial can be replicated in the Phase 3 trial.

Phase 3 Trials to be Conducted for Two Types of Hypertrophic Cardiomyopathy

Braveheart plans to initiate the global Phase 3 LIONHEART-HCM trial for symptomatic oHCM in the second half of 2026, and the NOBLEHEART-HCM Phase 3 trial for non-obstructive HCM (nHCM) in the first half of 2027. Hengrui Pharma is conducting a Phase 3 oHCM trial (NCT07021976) and a Phase 2 nHCM trial in China. nHCM represents an area with no approved cardiac myosin inhibitors, so success could open up a new patient population beyond the existing oHCM market. Conversely, if the results of the China-based Phase 2 trial are not replicated in multi-regional Phase 3 trials, both the development timeline and funding requirements could increase.

Competes with an Already Established Myosin Inhibitor Market

The primary comparator drugs are Camzyos (mavacamten) from Bristol Myers Squibb (BMY) and Myqorzo (aficamten) from Cytokinetics, Incorporated (CYTK), both of which target cardiac myosin. The FDA approved Camzyos on April 28, 2022, and Myqorzo on December 22, 2025, for symptomatic adult oHCM. Camzyos generated global sales of $1.1 billion in 2025, and the global HCM treatment market is projected to reach $1.4 billion in 2025 and $2.2 billion in 2033, demonstrating commercial demand. BHB-1893 needs to demonstrate superiority in terms of ease of administration, the need for dose adjustment, the burden of echocardiographic monitoring, and safety compared to these two approved drugs.